| Objective: To investigate the dynamic changes and clinical significance of inflammatory markers,tumor markers and immune cell markers in patients with lung cancer before and after multi-cycle treatment.Methods: A total of 46 patients with lung tumors admitted to our hospital from January 2015 to June 2022 were selected as the research objects.Blood routine(white blood cell count,neutrophil count)was detected by Minray automatic 5-class blood cell counter BC-5500,and tumor markers(AFP,CEA,CA125,CA153,CA199,CA724,CYFRA21-1,squamous cell carcinoma antigen,NSE)were detected by Roche electrochemiluminescence immunoassay analyzer Three indicators of acute infection(C-reactive protein,procalcitonin,interleukin-6)were detected by egg biological detection reagent,and immune cells(CD3+,CD3+CD4+,CD3+CD8,CD3+CD4+/CD3+CD8+,CD3-CD19+,CD3-(CD16+/CD56+))were detected by flow cytometry.The changes in the expression levels of biomarkers in peripheral blood of 46 lung cancer patients before and after multi-cycle treatment were analyzed.Results:1.In lung cancer,CEA(I+II 2.466±0.945(ng/m L),III+IV21.491±37.246(ng/m L)),CA125(I+II 30.056±22.48(U/m L)),stage III+IV92.513±163.929(U/m L)),CYFRA21-1(stage I+II 2.796±2.74(ng/m L),stage III+IV 9.665±12.068(ng/m L)),NSE(stage I+II 12.25±4.964(ng/m L))III+IV30.392±28.469(ng/m L)),CD3-(CD16+/CD56+)(I+II 7.961±2.067(%),III+IV13.362±9.767(%))I+II expression level was lower than that of III+IV.There was statistical significance(P<0.01).CA125(stage I+II 30.056±22.48 U/m L,stage III+IV 92.513±163.929 U/m L),CA153(stage I+II 13.727±8.248U/m L),III+IV 35.285±54.008(U/m L)),CA199(I+II 19.146±23.34(U/m L),III+IV 86.304±190.306(U/m L))I+II stage expression levels were lower than those of III+IV stage.There was statistical significance(P<0.05).There was no significant difference in other indicators(P> 0.05).2.Among different pathological types of lung cancer(squamous cell carcinoma,adenocarcinoma,small cell lung cancer),the expression level of SCC antigen(squamous cell carcinoma 5.627± 9.876(ng/m L),adenocarcinoma 0.913± 0.455(ng/m L),small cell lung cancer 1.058±0.449(ng/m L))in squamous cell carcinoma was higher than that in small cell lung cancer and adenocarcinoma.There was statistical significance(P<0.05).The expression level of CD3-CD19+(squamous cell carcinoma 7.987±4.371(%),adenocarcinoma 6.257±3.175(%),small cell lung cancer 10.295 ± 4.349(%))in small cell lung cancer was higher than that in adenocarcinoma and squamous cell carcinoma(P<0.05).There was no significant difference in other indicators(P> 0.05).3.In patients with lung cancer,every two cycles compared with before chemotherapy,serological indicators: 2 cycles: White blood cell count(before chemotherapy 7.165 ±1.905(g/L),2cycles 5.99±3.129(g/L)),neutrophil count(before chemotherapy4.73 ± 1.69(g/L),2 cycles 3.773 ± 2.812(g/L)),procalcitonin(before chemotherapy 5.909 ± 12.219(ng/m L))0.672 ± 1.271(ng/m L)in 2 cycles,and NSE(27.631±27.038(ng/m L)before chemotherapy,18.064±10.807(ng/m L)in2 cycles)were lower than those before chemotherapy(P<0.05).The expression of CD3+CD4+/CD3+CD8+(before chemotherapy 1.904 ± 0.781,2cycles 3.278 ± 4.699)was higher than that before chemotherapy,and the difference was statistically significant(P<0.05).The other indicators had no statistical significance(P>0.05).4 cycles: Procalcitonin(before chemotherapy5.909 ± 12.219(ng/m L),4 cycles 0.254 ± 1.291(ng/m L)),NSE(before chemotherapy 27.631 ± 27.038(ng/m L)),4 cycles 16.836 ± 7.445(ng/m L)),CA125(before chemotherapy 83.009 ± 152.559(U/m L),4 cycles 34.62 ±49.346(U/m L))were significantly lower than those before chemotherapy(P<0.05).The expression level of CD3-(CD16+/CD56+)(12.54 ± 9.218(%)before chemotherapy and 39.69 ± 54.577(%)after 4 cycles of chemotherapy)was significantly higher than that before chemotherapy(P<0.05).The other indicators had no statistical significance(P> 0.05).6 cycles: Procalcitonin(before chemotherapy 5.909 ± 12.219(ng/m L),6 cycles 0.954 ± 1.88(ng/m L)),NSE(before chemotherapy 27.631 ± 27.038(ng/m L)),6 cycles 17.312 ±8.903(ng/m L)),CA199(before chemotherapy 76.084 ± 176.778(U/m L),6cycles 17.654 ± 15.86(U/m L)),CD3+CD4+/CD3+C The expression level of D8+(before chemotherapy 1.904 ± 0.781,6 cycles 1.414 ± 0.617)was lower than that before chemotherapy,and the difference was statistically significant(P<0.05).Other indicators had no statistical significance(P>0.05).4.Serum biomarkers in patients with stable disease compared with pre-chemotherapy: 2cycles: White blood cell count(before chemotherapy 7.065 ± 1.805(g/L),2cycles 5.99± 3.129(g/L)),neutrophil count(before chemotherapy 4.65± 1.63(g/L),2 cycles 3.75±2.537(g/L)),procalcitonin(before chemotherapy 5.816±12.30(ng/m L),2 Cycle 0.466 ± 1.125(ng/m L)),NSE(before chemotherapy27.521 ± 27.253(ng/m L),2 cycles 18.154 ± 12.314(ng/m L))were significantly lower than those before chemotherapy(P<0.05).There was no significant difference in other indicators(P> 0.05).4 cycles: Procalcitonin(before chemotherapy 5.816 ± 12.30(ng/m L),4 cycles 0.07 ± 0.039(ng/m L),NSE(before chemotherapy 27.521 ± 27.253(ng/m L)),4 cycles 17.087 ±8.769(ng/m L))expression levels were lower than those before chemotherapy.There was statistical significance(P<0.05).There was no significant difference in other indicators(P> 0.05).6 cycles: White blood cell count(before chemotherapy 7.065 ± 1.805(g/L),6 cycles 5.679 ± 2.763(g/L)),neutrophil count(before chemotherapy 4.65 ± 1.63(g/L),6 cycles 3.457 ±2.413(g/L)),procalcitonin(before chemotherapy 5.816 ± 12.30(ng/m L)),6cycles 0.906 ± 1.646(ng/m L)),NSE(before chemotherapy 27.521 ±27.253(ng/m L)),6 cycles 15.741 ± 4.95(ng/m L)),CA724(before chemotherapy 14.125±49.857(U/m L)),6 cycles 3.001±2.139(U/m L)),CA199(before chemotherapy 75.04 ± 175.698(U/m L),6 cycles 18.315 ±14.589(U/m L)),CYFRA21-1(before chemotherapy 8.522 ± 11.631(ng/m L),6cycles 2.538± 2.012(ng/m L)),CD3+CD4+/CD3+CD8+(before chemotherapy1.924±0.801,6 cycles 1.28±0.545)were significantly lower than those before chemotherapy(P<0.05).The expression levels of CD3-CD19+(before chemotherapy 7.525 ± 4.005(%),6 cycles 45.311 ± 2.292(%))were significantly higher than those before chemotherapy(P<0.05).Other indicators had no statistical significance(P > 0.05).Conclusion: 1.In lung cancer,the expression levels of CEA,CA125,CYFRA21-1,NSE,CA153,CA199,CD3-(CD16+/CD56+)in stage I+II were lower than those in stage III+IV.2.In lung cancer,SCC antigen is highly expressed in squamous cell carcinoma.CD3-CD19+ is highly expressed in small cell lung cancer.3.The serum biological indexes of patients with lung cancer after multi-cycle chemotherapy were different from those before chemotherapy.4.The serum biological indexes of patients with stable lung cancer after multicycle chemotherapy have different degrees of changes compared with those before chemotherapy. |
PDF Full Text Request